Back to top
more

Genomic Health, Inc. (GHDX)

(Delayed Data from NSDQ)

$67.55 USD

67.55
321,603

+1.67 (2.53%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.63 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 11.8% in Session

AVEO Pharmaceuticals (AVEO) was a big mover last session, as the company saw its shares rise more than 11% on the day amid huge volumes.

    Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues

    Strong performance in the Instruments & Accessories as well as Systems segments drove Intuitive Surgical's (ISRG) top line in Q2.

      Neogen (NEOG) Earnings and Revenues Beat Estimates in Q4

      Neogen (NEOG) sticks to its four-pronged growth strategy for steady progress. Also, the company's accretive buyouts and its broader international base are a boon.

        Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?

        Align Technology (ALGN) poised to gain on continued strength in all geographies in Q2.

          Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up

          Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.

            Haemonetics Gains on Strong Plasma, Wider Global Footprint

            Strong growth of Haemonetics' (HAE) plasma-derived biopharmaceuticals is attributable to solid end-market demand.

              Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year?

              Is (GHDX) Outperforming Other Medical Stocks This Year?

                Is Genomic Health (GHDX) Stock Outpacing Its Medical Peers This Year?

                Is (GHDX) Outperforming Other Medical Stocks This Year?

                  Here's Why You Should Hold Onto Opko Health (OPK) Stock Now

                  Opko Health's (OPK) strong focus in R&D bodes well. However, the company faces cutthroat competition in the niche space.

                    AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife

                    AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.

                      Veeva Systems' Development Cloud Platform Picked by Idorsia

                      Switzerland's Idorsia implements Veeva Systems' (VEEV) Development Cloud. Veeva Systems gains foothold in Europe.

                        J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay

                        The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.

                          Can Rhythm and Neuro Aid Boston Scientific (BSX) Q2 Earnings?

                          Boston Scientific (BSX) set to ride high on strength in Rhythm and Neuro business in Q2.

                            Here's Why You Should Add Inogen (INGN) to Your Portfolio

                            Inogen's (INGN) solid product portfolio is a key catalyst. Also, the company benefits from strong focus in Europe.

                              Here's Why You Should Invest in DaVIta (DVA) Stock Right Now

                              Strong fundamentals and solid international presence make DaVita (DVA) a lucrative pick.

                                QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe

                                QIAGEN's (QGEN) HPV sales in the United States remain tepid. Weak APAC sales are due to bleak applied testing business.

                                  Here's Why You Should Add Edwards Lifesciences (EW) Now

                                  We are upbeat about Edwards Lifesciences' (EW) strong transcatheter valve sales in the domestic market as well as overseas.

                                    Here's Why You Should Invest in BioScrip (BIOS) Right Now

                                    We are upbeat about BioScrip's (BIOS) progress in the last reported quarter, courtesy of its multi-faceted CORE plan to improve financial position.

                                      Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?

                                      Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.

                                        Achillion's 3rd Factor D Inhibitor Enters Clinical Studies

                                        Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.

                                          Here's Why You Should Hold Intuitive Surgical (ISRG) Stock

                                          Strong performance by Intuitive Surgical's (ISRG) flagship da Vinci system is a key growth driver. However, the company faces stiff competition in the niche space.

                                            Panel Of Zacks Experts headshot

                                            Top Stock Picks for the Week of July 9th

                                            Two Outperforming Companies in the Healthcare arena.

                                              Why You Should Add Boston Scientific (BSX) to Your Portfolio

                                              Boston Scientific's (BSX) agreement for Cryterion Medical buyout in the field of atrial fibrillation buoys investor optimism on the stock.

                                                Abaxis (ABAX) and Zoetis Merger Deal Crosses HRS Hurdle

                                                With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.

                                                  Zoetis (ZTS) Tides Over HSR Hurdle for Abaxis Acquisition

                                                  Zoetis' (ZTS) waiting period under the HSR Act ends. It is related to its proposed merger with Abaxis for a purchase consideration of roughly $2 billion in aggregate.